ArticleSAGE open medicine2026
Expressional and prognostic value of cytokine receptor-like factor 3 in liver hepatocellular carcinoma patients via integrated bioinformatics analyses and experiments.
Article in SAGE open medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cytokine Receptor-like Factor 3 (CRLF3) and Its Emerging Roles in Neurobiology, Hematopoiesis and Related Human Diseases.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver hepatocellular carcinoma is a highly prevalent and lethal malignancy. The orphan cytokine receptor-like factor 3, although evolutionarily conserved and implicated in hematopoiesis and neuroprotection, remains poorly characterized in liver hepatocellular carcinoma. Objective: To investigate the expression pattern of cytokine receptor-like factor 3 in liver hepatocellular carcinoma and its association with clinicopathological characteristics, prognosis, and potential biological functions through bioinformatics analysis. Methods: Cytokine receptor-like factor 3 mRNA and protein expression in liver hepatocellular carcinoma were evaluated using the cancer genome atlas, human protein atlas, immunohistochemistry, and qPCR. The association of cytokine receptor-like factor 3 expression with prognosis and clinicopathological features was assessed using Kaplan-Meier survival analysis, Cox regression, logistic regression, and receiver operating characteristic curves. Potential functional pathways associated with cytokine receptor-like factor 3 were explored using gene ontology, Kyoto encyclopedia of genes and genomes, gene set enrichment analysis, and ssGSEA. Results: Cytokine receptor-like factor 3 expression was significantly elevated in liver hepatocellular carcinoma tissues and correlated with poorer overall survival, disease-specific survival, and progression-free interval. High cytokine receptor-like factor 3 expression was associated with advanced T stage, pathologic stage, histologic grade, and elevated alpha-fetoprotein levels, and emerged as an independent prognostic factor. Receiver operating characteristic curve analysis suggested a potential diagnostic value for cytokine receptor-like factor 3 in distinguishing liver hepatocellular carcinoma tissues from normal tissues. Enrichment analysis indicated that genes correlated with cytokine receptor-like factor 3 are enriched in pathways such as PI3K/Akt, Wnt, and JAK/STAT, as well as immune-related processes. Notably, cytokine receptor-like factor 3 expression showed a strong positive correlation with Th2 cell infiltration. Conclusions: This study reveals that cytokine receptor-like factor 3 is overexpressed in liver hepatocellular carcinoma and is associated with poor patient prognosis and immune infiltration. These findings suggest that cytokine receptor-like factor 3 may serve as a promising candidate prognostic biomarker and warrants further investigation as a potential immunotherapeutic target in liver hepatocellular carcinoma. The mechanistic hypotheses generated here provide a foundation for subsequent experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.